Previous 10 | Next 10 |
2023-07-20 07:07:34 ET Johnson & Johnson ( NYSE: JNJ ) added ~2% in the pre-market Thursday after the pharma giant exceeded Wall Street forecasts with its Q2 2023 results, thanks mainly to better-than-expected results from its Pharmaceutical and MedTech segments. The New...
2023-07-07 11:50:52 ET Summary Legend's recently-leaked data showed Carvykti's prowess in earlier line MM patients. Analysts predict blockbuster potential in these earlier lines. Although looking expensive, there's potential for growth here on revenue expansion. Despite ...
2023-07-07 07:44:52 ET BTIG technical strategist Jonanthan Krinsky is expecting a retracement for the broader market in the second half of the year following the strong gains so far. "If the year was over right now, it would be the NDX’s ( COMP.IND ) ( QQQ ) ninth best ye...
2023-07-06 14:48:32 ET Summary Johnson & Johnson's Supplemental Biologics Licensing Application of CARVYKTI was filed; approval would allow company to target a much earlier Multiple Myeloma patient population. Sales of CARVYTKI have not ramped up well since launch, but efforts...
2023-06-11 08:30:00 ET Summary Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. Shanghai Fosun Pharma will partner with World Bank affiliate International Finance C...
The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy and safety of cell therapy as ear...
First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study investigating the efficacy of a cell therapy versus standard of care (DPd or PVd) as early as after...
2023-05-26 10:45:42 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – May 26, 2023 – USA News Group – The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 20...
2023-05-25 14:07:05 ET Legend Biotech ( NASDAQ: LEGN ) said Johnson & Johnson's ( NYSE: JNJ ) unit Janssen-Cilag International filed an application to the European Medicines Agency (EMA) seeking expanded approval of blood cancer drug Carvykti. The Ty...
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therap...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...